Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, ...
Detailed price information for Processa Pharmaceuticals Inc (PCSA-Q) from The Globe and Mail including charting and trades.
In a report released today, Patrick Wood from Morgan Stanley maintained a Sell rating on Baxter International, with a price target of $15.00. The company’s shares closed last Tuesday at $20.74.
March 9 - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines. Although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results